Samira Ansari, a member of the research group in charge of the raw materials production, says the raw materials have been produced by a knowledge-based company in Iran.
In an interview with Mehr News Agency, Ansari said highly skilled human resources, production technologies and market are among the main indexes in biotechnology industry and added Iran enjoys good records in all these fields.
She went on to say that the transfer of technology from the West to Iran and other developing states is carried out rarely, and thus such technologies need to be developed inside the country.
According to Ansari, added value and dual use technologies are the main concerns by the West that hampers the transfer of technology.
Most Western companies only share the formula of their materials and sell protein raw materials with added value and high technological capacity, she noted.
“Interferon Beta-1, Paratiroid Hormone, form pig Filgrastim, growth hormone, Adalimumab, Sinal F are the raw materials for cancer and MS treatment which have been produced by Iranian scientists,” Ansari said.
Produced with international standards, the materials are used in the production of caner and MS medicines, she added, stressing that the materials are the fruits of Iranian and foreign scientists’ cooperation in various areas.
Such production can prevent the exit of currencies from Iran and help the country’s crisis-hit economy.